[
    [
        {
            "time": "2019-03-28",
            "original_text": "药明康德（603259）2019年年报点评：收入增长提速，龙头地位显著",
            "features": {
                "keywords": [
                    "药明康德",
                    "收入增长",
                    "龙头地位"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德（603259）2019年年报点评：收入增长提速，龙头地位显著",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-02-15",
            "original_text": "北向资金逆势加仓医药股，抛售美的集团6亿元丨牛熊眼",
            "features": {
                "keywords": [
                    "北向资金",
                    "加仓",
                    "医药股",
                    "抛售",
                    "美的集团"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "家电"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "北向资金逆势加仓医药股，抛售美的集团6亿元丨牛熊眼",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-04-05",
            "original_text": "【万联医药|年报点评】药明康德：主营业务增长稳健，一体化平台优势凸显",
            "features": {
                "keywords": [
                    "药明康德",
                    "主营业务",
                    "增长稳健",
                    "一体化平台"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【万联医药|年报点评】药明康德：主营业务增长稳健，一体化平台优势凸显",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-04-10",
            "original_text": "【国信医药】药明康德：收入增长提速，龙头地位显著丨2019年报点评",
            "features": {
                "keywords": [
                    "药明康德",
                    "收入增长",
                    "龙头地位"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【国信医药】药明康德：收入增长提速，龙头地位显著丨2019年报点评",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-03-12",
            "original_text": "异动直击|股东拟减持不超过1%的A股，药明康德跌超6% 拟减持股份",
            "features": {
                "keywords": [
                    "药明康德",
                    "减持",
                    "异动"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "异动直击|股东拟减持不超过1%的A股，药明康德跌超6% 拟减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-03-08",
            "original_text": "【民生医药|周报】推荐疫情影响下“供-需”端增速分化带来投资机会",
            "features": {
                "keywords": [
                    "疫情",
                    "供需",
                    "增速分化",
                    "投资机会"
                ],
                "sentiment_score": 0.65,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【民生医药|周报】推荐疫情影响下“供-需”端增速分化带来投资机会",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-03-13",
            "original_text": "药明康德H股跌近7% 股东拟减持A股 拟减持股份",
            "features": {
                "keywords": [
                    "药明康德",
                    "H股",
                    "减持",
                    "下跌"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药明康德H股跌近7% 股东拟减持A股 拟减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-15",
            "original_text": "【东北医药崔洁铭】药明康德（603259）年报点评：业绩稳定增长，四大业务持续赋能",
            "features": {
                "keywords": [
                    "药明康德",
                    "业绩增长",
                    "四大业务",
                    "赋能"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【东北医药崔洁铭】药明康德（603259）年报点评：业绩稳定增长，四大业务持续赋能",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]